JPMorgan says this pure play water stock is cheap and can jump nearly 20%

JPMorgan initiated coverage of Xylem (XYL) with an overweight rating and a $148 price target, implying a 17.8% upside, citing the company's leading position in the water technology sector and attractive valuation relative to historical averages. Analyst Mark Strouse highlighted Xylem's diversified end markets, secular tailwinds, and opportunities for margin expansion through its 80/20 simplification strategy and the integration of Evoqua as key drivers for future growth, positioning Xylem as a strong long-term holding for industrial and sustainability-focused investors.

Analysis

JPMorgan has initiated coverage on Xylem Inc. (XYL) with an overweight rating and a $148 per share price target, suggesting a potential 17.8% upside from current levels. This positive outlook stems from Xylem's position as a leading pure-play water technology company with diversified exposure to resilient water end markets, many of which benefit from multi-decade secular tailwinds. Analyst Mark Strouse highlighted that Xylem is currently trading at a discount to its historical averages, presenting an attractive entry point for investors. The company's portfolio includes prominent brands such as Evoqua, Flygt, and Sensus; Evoqua, in particular, is seen as having significant global expansion opportunities due to its relationships with Fortune 500 companies and Xylem's international service footprint. Sensus, acquired in 2016, is a major player in the water metering market. Furthermore, Xylem's strategy implemented in 2023, focusing on 80/20 simplification efforts, capitalizing on the Per- and Polyfluoroalkyl Substances (PFAS) remediation opportunity, and integrating Evoqua, is expected to drive margin growth through fiscal 2027 and potentially lead to outperformance against medium- to longer-term investor expectations. Year to date, Xylem shares have appreciated by 8.3%.

Key Decisions for Investors

• Investors seeking exposure to water technology and sustainability themes may consider Xylem an attractive core long-term holding, given its industry leadership and diversified end markets.
• The current valuation, noted as a discount to historical averages, could represent a favorable entry point for accumulating a position.
• Monitor the progress of Xylem's 80/20 simplification strategy, Evoqua integration, and developments in the PFAS market, as these are key catalysts for potential margin expansion and outperformance.
• Consider the 17.8% upside implied by JPMorgan's $148 price target when evaluating potential returns, aligning with a bullish sentiment on the stock.